2016 Scientific Committee

Ana Barac, MD, PhD, FACC

Noninvasive cardiologist; Director of the Cardio-Oncology Program, MedStar Heart and Vascular Institute; Assistant Professor of Medicine, Georgetown University, Washington, DC, USA

founder

Ana Barac, MD, PhD, is a noninvasive cardiologist at MedStar Heart and Vascular Institute and an Assistant professor of Medicine at Georgetown University. Her clinical and research interests focus on the mechanisms, diagnosis and treatment of cardiac complications of cancer therapies and she leads MedStar Heart and Vascular Institute’s Cardio-Oncology program.

Read More...

Dr. Barac has basic science research background in signaling pathways and in vascular physiology research on endothelial function. She previously was a research fellow at the National Institute of Dental and Craniofacial Research, National Institutes of Health. She holds KL2 Scholar Award from the Georgetown-Howard Universities Center for Clinical and Translational Science for investigations of cardiovascular toxicity in patients with breast cancer. Her clinical cardiac imaging expertise includes advanced training in cardiac MR and echocardiography. Dr. Barac led the Cardio-Oncology Working group within the American College of Cardiology (ACC) and was appointed chair of the new ACC Cardio-Oncology Council in 2015. She serves on the editorial boards of the Journal of the American College of Cardiology (JACC), the Journal of Cardiovascular Translational Research and the Cardio-Oncology journal.

Christine Brezden-Masley, MD, PhD, FRCPC

Medical Oncologist, St. Michael's Hospital, Toronto, ON, Canada

founder

Dr. Christine Brezden-Masley is a practicing Medical Oncologist and the Division Head of Hematology / Oncology at St. Michael’s Hospital in Toronto and is the Head of the Oncology Clinical Research Group there. She obtained her PhD in Medical Biophysics at Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Assistant Professor at the University of Toronto.

Read More...

She is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto Region. She treats both Breast and GI (colorectal and gastric cancers) malignancies and these are the major areas of her clinical research. Her main area of clinical research is cardiotoxicity from cancer therapy and is the Co-Chair of the annual Canadian Cardio-Oncology Network meeting, a collaborative national meeting improving cardiac heath in cancer patients. She is active in research, education and has been instrumental in the clinical development of the cancer program at St. Michael’s Hospital.

Giuseppe Curigliano, MD, PhD

Medical Oncologist; Director of the Division of Experimental Therapeutics, European Institute of Oncology, Milan, Italy

founder

Giuseppe Curigliano, MD, PhD, is Chair of the Division of Early Drug Development at the European Institute of Oncology, in Milan, Italy, where besides his clinical work, he is a clinician and researcher specializing in breast cancer. Dr. Curigliano earned his MD at the Universita’ Cattolica del Sacro Cuore, in Rome, Italy. He also holds a PhD in clinical pharmacology from the University of Pisa.

Read More...

He completed his postdoctoral fellowship in South Carolina Medical School, Charleston (1993-1994) working on clinical immunology studies in solid tumors. He moved to the Comprehensive Cancer Center at Columbia University in New York City, NY, USA (1995-96). This working experience was concentrated on molecular epidemiology studies related to carcinogen-DNA adducts, susceptibility genes characterization in solid tumors; gene-environment interactions and development of monoclonal antibodies for carcinogen DNA-adducts detection. He moved to the European Institute of Oncology in 1999. He applied to clinical research his strong basic science background leading several translational research protocols on breast and urogenital cancer. He was committed for 3 years in the phase I unit, contributing to the successful development of several targeted agents and cytotoxics. Since 2001 he is an assistant professor of Clinical Pharmacology at University of Milan. In 2010 he visited Dana Farber Cancer Institute, Harvard Medical School, Boston, USA. He is co-chair of the Division of Clinical Oncology coordinating clinical and comprehensive management of patients with all solid tumors (lung, gastrointestinal, urogenital, breast, soft tissue sarcomas and rare tumors). His clinical experience is based on a daily clinical management of patients with solid tumours, within a comprehensive cancer center accepting every year at least 85.000 first diagnosis patients. He practices in the in-patient, out-patient and day-hospital setting. He served for 3 years on emergency and palliative care section of the Division. He is an active member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) and the Associazione Italiana di Oncologia Medica (AIOM). He is founding member of/and scientific coordinator for the International Cardio-Oncology Society (ICOS). He serves on the Clinical Research Committee of the AIOM. He serves as a faculty member in the European School of Oncology (ESO). He is a member of the Scientific Advisory Committee of the International Breast Cancer Study Group (IBCSG) and of the Breast International Group (BIG). He is an ESMO and ESO Faculty Member for Breast Cancer. He served on the Program Scientific Committee of ESMO 2012 and 2013. He served on the Program Scientific Committee of the St Gallen conference 2009, 2011 and 2013 as scientific secretary. Since October 2011 to May 2012 he served as a Susan G. Komen for the Cure Scholar. He served on the Program Scientific and Executive Committees of the IMPAKT Breast Cancer Conference 2013 and served ad Chair of the metastatic breast cancer track for ESMO 2014 meeting in Madrid.  Dr. Curigliano’s research experiences include principle or coinvestigator work in several phase I-II clinical trials with targeted agents, cytotoxic and endocrine agents in breast cancer. He has been also involved as principal investigator in several phase I studies with peptide vaccines for breast cancer (either in the adjuvant either in the metastatic setting). Dr Curigliano's research interests include the biology of breast cancer, predictive markers of response to therapy and new anti-cancer agents. He is the coordinator of a research platform on new drug development in breast cancer at the European Institute of Oncology. Dr. Curigliano has written widely on oncology, including articles in the Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer (more than 160 peer reviewed article, most of them as first author) and several book chapters. He also reviews for a number of journals, including the Journal of Clinical Oncology, Annals of Oncology, the Journal of the National Cancer Institute, the European Journal of Cancer and many other “breast oriented journals”. He is member of the Editorial Board of Journal of Clinical Oncology and Annals of Oncology. He serves in the press committee of the European Society of Medical Oncology as Spokesperson coordinator for breast cancer.

Zaza Iakobishvili, MD, PhD

Director of Emergency Cardiology Services and Cardio-Oncology Clinic, Department of Cardiology, Rabin Medical Center, Tel Aviv University, Petah-Tikva, Israel

founder

Zaza Iakobishvili is a director of Emergency Cardiology Services and Cardio-oncology clinic at the Beilinson hospital in Rabin Medical Center, Petah Tikva. He received his medical degree in 1988 from the Tbilisi State Medical University and completed his postdoctoral training in Tbilisi Institute of Human Physiology. In 1996 he immigrated to Israel, completed 2-year residency in Internal medicine and received Board certification in Internal medicine after successful completion of qualifying examinations.  

Read More...

He applied to cardiology fellowship in the Department of Cardiology, Rabin Medical Center and successfully passed Board certification examinations in cardiology in 2001. He worked as attending physician in the cardiac intensive care unit from 2002 till 2009 when he was appointed to lead Emergency Cardiology Services. In 2008-2010 was appointed to the secretary of National Cardiology Board examination committee. From 2009 he is a secretary of Biennial International Meeting on Acute Cardiac Care. From 2011 he was elected secretary of Israel working group on Acute Cardiac Care. From 2015 he serves elected chairman of the working group on Acute Cardiac Care in Israel Heart Society. Zaza Iakobishvili is actively engaged in teaching at the Sackler Faculty of Medicine at the University of TelAviv, repeatedly named among “best teachers” of the University. He is actively involved in scientific process and is author and co-author of more than 60 papers and book chapters, published in peer-reviewed journals in the field of cardiology as Am Heart J, Am J Cardiol, Int J Cardiol, etc. He is the author of chapters on cardiogenic shock in European Society of Cardiology Textbook on Acute Cardiac Care (2010), Medical Clinics of North of America, American Heart Association book on cardiogenic shock (2011). He presents on international medical meetings as invited faculty of ESC in 2007, ESC Acute Cardiac Care meeting in Copenhagen, 2010, Madrid, 2013, Vienna, 2015. In 2015 he presented on Joint Israel-France association of cardiology meeting “Biomarkers of Cardiotoxicity”. Now he takes active participation in the European Society of Cardiology Acute Cardiac Care Association working group on quality of acute care. He leads Acute Coronary Syndrome Israeli Registry (ACSIS). In 2016 ACSIS will be accomplished by prehospital data from MDA (“Magen David Adom” Israel largest emergency medical system), as well as by patient-level follow-up data from health management organizations database thus allowing for the first time to follow the individual patient from the beginning of ACS until the chronic phase and outpatient management. Main fields of scientific interest are: cardio-oncology, epidemiology of cardiotoxicity of anti-cancer therapy, prevention and treatment of cardiotoxicity, cardiogenic shock, acute coronary syndromes and acute heart failure, diabetes treatment in cardiac patients, cardiac biomarkers. In 2013 he established and leads the clinic of cardio-oncology where more than 1000 patients with cancer and heart problems are getting follow-up and treatment. Now he is organizing Israel registry on cancer treatment cardiotoxicity supported by the grant from Israel Association of Cardiovascular Trials.

Jose Lopez-Sendon, MD, PhD

Director, Department of Cardiology, Hospital Universitario La Paz Instituto de Investigación La PAZ, Madrid, Spain

founder

José Luis Lopez-Sendon is the Chief of the Cardiology Department, Chair of Cardiovascular Research at the Instituto de Investigación (IdiPaz) and Professor of Medicine at La Paz University Hospital in Madrid. He obtained his MD at the University of Valladolid in Spain and after his training in cardiology at the National School of Chest Diseases, he worked as a clinical cardiologist at La Paz Hospital (Universidad Autonoma, Madrid). While there, he earned his PhD and served as an associate professor of medicine.

Read More...

Professor Lopez-Sendon’s main fields of interest are acute coronary syndromes, heart failure and chronic ischemic heart disease. He has been a Board member and Councillor of the European Society of Cardiology, Chairman of the Scientific Board of the World Heart Federation, member of the Heart Failure Association, and General Secretary of the Spanish Society of Cardiology. He actively works in teaching and research programmes with the ESC, the American Heart Association and the World Heart Federation. He is a Foundation Fellow of the ESC and a Fellow of the American College of Cardiology. He has published over 800 articles in peer-reviewed journals. He has been National Coordinator of the Euro Heart Survey program of the ESC, member of the Guideline Committee of the ESC, and member of the Steering Committees of numerous trials in acute coronary syndromes, secondary prevention, heart failure and atrial fibrillation.

Michael J. Mauro, MD

Leader, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

founder

Dr. Michael Mauro is a board-certified hematologist, professor, and leader of the Myeloproliferative Neoplasms Program, Leukemia Service, Memorial Sloan Kettering Cancer Center in New York City. After receiving his BS and MD from Dartmouth College and Dartmouth Medical School in New Hampshire, he completed both residency and fellowship training at the New York-Presbyterian Hospital/Weill Cornell Medical College in Manhattan.

Read More...

Before joining Memorial Sloan Kettering, Dr. Mauro was on the faculty of Oregon Health and Sciences University for 13 years, where he directed the CML clinical trial program and was involved in the early development and sentinel clinical studies of ABL kinase inhibitors for CML. Dr. Mauro’s clinical expertise is in treating patients with chronic myeloid leukemia (CML) as well as other myeloproliferative disorders, including myelofibrosis, polycythemia, and thrombocytosis as well as less common conditions such as eosinophilic and mast cell disorders. He holds positions on the boards of the International CML Foundation, the MAX Foundation, and the Leukemia and Lymphoma Society.

Javid Moslehi, MD

Director, Vanderbilt Cardio-Oncology, Vanderbilt University Medical Centre, Nashville, TN, USA

founder

Dr. Moslehi is an Assistant Professor of Medicine and the Director of the Cardio-Oncology Program at Vanderbilt School of Medicine. He graduated from Johns Hopkins University and University of Connecticut School of Medicine. He then completed an internal medicine residency at Johns Hopkins Hospital.

Read More...

Following the completion of clinical cardiology fellowship at the Brigham and Women's Hospital and Harvard Medical School, he started a basic science post-doctoral fellowship at the Dana-Farber Cancer Institute focusing on the role of angiogenesis (formation of new blood vessels) in heart disease. In 2009, he founded the Cardio-Oncology program at Brigham and Women's Hospital/Dana-Farber Cancer Institute and Harvard Medical School with a clinic and research program focused on the cardiovascular care for cancer patients and cancer survivors. In 2014, he joined Vanderbilt. Dr. Moslehi is an expert clinician on the management of cardiac complications associated with radiation and both novel and traditional chemotherapies. His clinic and research program is focused on the mechanisms of toxicities associated with novel targeted therapies and how this knowledge can be modulated to understand human cardiovascular biology.

Negar Mousavi, MD

Director, Cardio-Oncology Program, McGill University Health Centre, Montreal, QC, Canada

Dr. Negar Mousavi is an assistant professor of medicine at McGill University. Her advanced training was in multi-modality cardiovascular imaging including echocardiography, cardiac MRI, cardiac CT and nuclear cardiology. She is the director of the Cardio-Oncology program at McGill University Health Center. Her research interest is in the utility of advanced imaging techniques for detection of subclinical cancer-therapy related micro- and macrovascular disease.

Edith Pituskin, RN, PhD

Assistant Professor of Nursing, Edmonton Clinic Health Academy, University of Alberta, Edmonton, AB, Canada

founder

Sandra Swain, MD

Medical Oncologist; Medical Director, Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, USA

Dinesh Thavendiranathan, MD

Cardiologist; Assistant Professor of Medicine; Director, Ted Rogers Program in Cardiotoxicity Prevention, Toronto General Hospital, University Health Network, Toronto, ON, Canada

founder

Dr. Dinesh Thavendiranathan is a cardiologist at the Toronto General Hospital, University of Toronto. He is an assistant professor of medicine and a clinician investigator.  His training was in advanced cardiovascular imaging and his current clinical practice involves work with cardiac MRI, CT, and echocardiography.

Read More...

He is the Director of the Ted Rogers Program in Cardiotoxicity Prevention which focuses on cardiac toxicity from systemic therapies including cancer therapy. His research focus is in the use of advanced cardiac imaging techniques for detection and management of cardiac toxicity.

Ronald Witteles, MD

Associate Professor of Medicine, Internal Medicine Residency Program Director, Stanford University School of Medicine, Stanford, CA

founder

Dr. Witteles leads Stanford University’s Cardio-Oncology clinic and is Co-Director of the Stanford Amyloid Centers, one of the nation’s largest multidisciplinary groups devoted to amyloidosis. He earned his B.A. at Northwestern University followed by an M.D. with Honors from The University of Chicago Pritzker School of Medicine.

Read More...

He then completed Internal Medicine residency at Stanford University (including an additional year as Chief Resident), followed by fellowship training in Cardiovascular Medicine (including serving as Chief Fellow). Following fellowship, Dr. Witteles joined the faculty at Stanford as a member of the Heart Failure team. Dr. Witteles founded Stanford’s Cardio-Oncology clinic and co-founded the Stanford Amyloid Centre in 2008. He has led and collaborated on a multitude of clinical and translational research studies in Cardio-Oncology, amyloidosis, and cardiac sarcoidosis. His other primary role is as Program Director for the Stanford University Internal Medicine residency training program, in which he leads a program of 120 housestaff, and oversees all of the fellowship programs within the Department of Medicine.